GlassScriptPhysician profile
Elizabeth Huffman
NPI 1043067697
$1,398.42
in general payments reported to CMS, 2019-2025
20 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $194 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $271.46 | 2024-2025 | Caplyta |
| Abbvie INC. | $253.00 | 2024-2025 | |
| Gilead Sciences, INC. | $116.14 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $115.15 | 2024-2025 | Airsupra |
| Exact Sciences Corporation | $105.58 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $95.15 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $65.19 | 2024-2025 | Bexsero, Rotarix, Pediarix |
| Corcept Therapeutics | $48.46 | 2025 | Korlym |
| Pfizer INC. | $47.54 | 2025 | |
| Lundbeck LLC | $42.57 | 2025 | Rexulti |
| Noven Therapeutics, LLC | $42.22 | 2025 | Xelstrym, Secuado |
| Dexcom, INC. | $39.88 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $33.08 | 2025 | Veozah |
| Alkermes, INC. | $30.07 | 2025 | Vivitrol |
| Janssen Pharmaceuticals, INC | $21.48 | 2025 | Spravato |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $16.51 | 2025 | Tonmya |
| Supernus Pharmaceuticals, INC. | $15.61 | 2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $14.51 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $13.48 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $11.34 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.